Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

AZN

AstraZeneca (AZN)

AstraZeneca PLC
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:AZN
日付受信時刻ニュースソース見出しコード企業名
2025/02/1501 : 10Business WireIMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trialNASDAQ:AZNAstraZeneca PLC
2025/02/1319 : 45PR Newswire (US)AstraZeneca PLC Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZNNASDAQ:AZNAstraZeneca PLC
2025/02/1019 : 45PR Newswire (US)Investors who lost money on AstraZeneca PLC(AZN) should contact The Gross Law Firm about pending Class Action - AZNNASDAQ:AZNAstraZeneca PLC
2025/02/0623 : 53Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
2025/02/0621 : 00Business WireAstraZeneca’s Full Year and Q4 2024 resultsNASDAQ:AZNAstraZeneca PLC
2025/02/0619 : 45PR Newswire (US)The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZNNASDAQ:AZNAstraZeneca PLC
2025/02/0614 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AZNAstraZeneca PLC
2025/02/0403 : 05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
2025/02/0320 : 23Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
2025/02/0319 : 45PR Newswire (US)Shareholders that lost money on AstraZeneca PLC(AZN) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreNASDAQ:AZNAstraZeneca PLC
2025/01/3019 : 45PR Newswire (US)AZN LAWSUIT ALERT: The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming DeadlineNASDAQ:AZNAstraZeneca PLC
2025/01/2808 : 00Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapiesNASDAQ:AZNAstraZeneca PLC
2025/01/2719 : 45PR Newswire (US)Shareholders of AstraZeneca PLC Should Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZNNASDAQ:AZNAstraZeneca PLC
2025/01/2404 : 33PR Newswire (Canada)AstraZeneca prévoit un investissement de 820 M$ CA (570 M$ US) au Canada pour consolider son statut grandissant de plaque tournante mondiale et faire progresser la réalisation d'essais cliniquesNASDAQ:AZNAstraZeneca PLC
2025/01/2404 : 32PR Newswire (Canada)AstraZeneca plans C$820 million (US$570m) investment in Canada to advance growing global hub and clinical deliveryNASDAQ:AZNAstraZeneca PLC
2025/01/2319 : 45PR Newswire (US)AstraZeneca PLC Sued for Securities Law Violations - Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZNNASDAQ:AZNAstraZeneca PLC
2025/01/2319 : 00PR Newswire (US)AstraZeneca PLC Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AZNNASDAQ:AZNAstraZeneca PLC
2025/01/2019 : 45PR Newswire (US)The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZNNASDAQ:AZNAstraZeneca PLC
2025/01/1807 : 35Business WireDATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancerNASDAQ:AZNAstraZeneca PLC
2025/01/1721 : 00Business WireCALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphomaNASDAQ:AZNAstraZeneca PLC
2025/01/1619 : 45PR Newswire (US)Shareholders that lost money on AstraZeneca PLC(AZN) should contact The Gross Law Firm about pending Class Action - AZNNASDAQ:AZNAstraZeneca PLC
2025/01/1321 : 00Business WireDatopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancerNASDAQ:AZNAstraZeneca PLC
2025/01/1319 : 45PR Newswire (US)Shareholders that lost money on AstraZeneca PLC(AZN) should contact The Gross Law Firm about pending Class Action - AZNNASDAQ:AZNAstraZeneca PLC
2025/01/0919 : 45PR Newswire (US)Shareholders that lost money on AstraZeneca PLC(AZN) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreNASDAQ:AZNAstraZeneca PLC
2025/01/0303 : 50PR Newswire (US)AstraZeneca PLC Class Action: The Gross Law Firm Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZNNASDAQ:AZNAstraZeneca PLC
2025/01/0300 : 42PR Newswire (US)AstraZeneca PLC Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AZNNASDAQ:AZNAstraZeneca PLC
2024/12/3019 : 45PR Newswire (US)Class Action Filed Against AstraZeneca PLC (AZN) - February 21, 2025 Deadline to Join - Contact The Gross Law FirmNASDAQ:AZNAstraZeneca PLC
2024/12/1823 : 05PR Newswire (Canada)Alexion, la division des maladies rares d'AstraZeneca, et l'Alliance pharmaceutique pancanadienne (APP) parviennent à un accord au sujet de Koselugo (sélumétinib) pour le traitement des enfants atteints de neurofibromatose de type 1 (NF1) présentant deNASDAQ:AZNAstraZeneca PLC
2024/12/1823 : 05PR Newswire (Canada)Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo (selumetinib) for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform nNASDAQ:AZNAstraZeneca PLC
2024/12/1200 : 15Business WireLYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trialNASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN